





COVAXIN™

PUBLICATIONS

Sr. No	Published	Title	Journal
1.	Phase 1 Human Clinical Trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.	THE LANCET Infectious Diseases
2.	Hamster Efficacy Study https://www.sciencedirect.com/science/article/pii/S2589004221000225	Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.	 CellPress

Sr. No	Accepted for Publication	Title	Journal
3.	Non-Human Primate Efficacy Study https://www.researchsquare.com/article/rs-65715/v1	Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques.	 nature COMMUNICATIONS
4.	Preclinical Safety and Immunogenicity https://doi.org/10.1101/2020.09.09.285445	Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152.	 CellPress

Sr. No	Under Advanced Peer Review	Title	Journal
5.	Phase 2 Human Clinical Trial https://doi.org/10.1101/2020.12.21.20248643	Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report.	medRxiv THE PREPRINT SERVER FOR HEALTH SCIENCES
6.	COVAXIN Immune responses effective against UK strain https://www.biorxiv.org/content/10.1101/2021.01.26.426986v1	Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum	 CSH Cold Spring Harbor Laboratory bioRxiv THE PREPRINT SERVER FOR BIOLOGY